Skip to main content Accessibility help
×
Home

Trends in Resistance to Carbapenems and Third-Generation Cephalosporins among Clinical Isolates of Klebsiella pneumoniae in the United States, 1999–2010

  • Nikolay P. Braykov (a1), Michael R. Eber (a2), Eili Y. Klein (a1) (a3), Daniel J. Morgan (a4) (a5) and Ramanan Laxminarayan (a1) (a6) (a7)...

Abstract

Objective.

Multidrug-resistant Enterobacteriaceae pose a serious infection control challenge and have emerged as a public health threat. We examined national trends in the proportion of Klebsiella pneumoniae isolates resistant to carbapenems (CRKP) and third-generation cephalosporins (G3CRKP).

Design and Setting.

Retrospective analysis of approximately 500,000 K. pneumoniae isolates cultured between January 1999 and July 2010 at 287 clinical laboratories throughout the United States.

Methods.

Isolates were defined as CRKP if they were nonsusceptible to 1 or more carbapenems and were defined as G3CRKP if they were nonsusceptible to ceftazidime, ceftriaxone, or related antibiotics. A multivariable analysis examined trends in the proportion of resistant isolates, adjusting for age, sex, isolate source, patient location, and geographic region.

Results.

The crude proportion of CRKP increased from less than 0.1% to 4.5% between 2002 and 2010; the frequency of G3CRKP increased from 5.3% to 11.5% between 1999 and 2010. G3CRKP and CRKP were more common among elderly patients (those greater than 65 years of age); the adjusted odds ratio (aOR) relative to pediatric patients (those less than 18 years of age) was 1.2 for G3CRKP (95% confidence interval [CI], 1.2–1.3) and 3.3 for CRKP (95% CI, 2.6–4.2). G3CRKP and CRKP were also more common among patients from the northeastern United States (aOR, 2.9 [95% CI, 2.8–3.0] and 9.0 [95% CI, 7.9–10.4]) than among those from the western United States. The prevalence of outpatient CRKP isolates increased after 2006, reaching 1.9% of isolates in our sample in 2010 (95% CI, 1.6%–2.1%).

Conclusions.

The frequency of G3CRKP and CRKP is increasing in all regions of the United States, and resistance is emerging among isolates recovered in the outpatient setting. This underscores the need for enhanced laboratory capacity and coordinated surveillance strategies to contain the further spread of these emerging pathogens.

Copyright

Corresponding author

Center for Disease Dynamics, Economics and Policy, 1616 P Street NW Suite 600, Washington, DC 20036 (ramanan@cddep.org)

References

Hide All
1. de Kraker, M, Wolkewitz, M, Davey, P, et al. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 2011;66(2):398407.
2. Prabaker, K, Weinstein, RA. Trends in antimicrobial resistance in intensive care units in the United States. Curr Opin Crit Care 2011;17(5):472479.
3. Paterson, D. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005;18(4):657686.
4. Pitout, JDD, Nordmann, P, Laupland, KB, Poirel, L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lacta-mases (ESBLs) in the community. J Antimicrob Chemother 2005; 56(1):5259.
5. Ramphai, R, Ambrose, PG. Extended-spectrum β-lactamases and clinical outcomes: current data. Clin Infect Dis 2006;42(suppl 4):S164S172.
6. Giske, CG, Monnet, DL, Cars, O, Carmeli, Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008;52(3):813–21.
7. Nordmann, P, Naas, T, Poirel, L. Global spread of carbapenemase-producing Enterobacteriaceae . Emerg Infect Dis 2011;17(10): 17911798.
8. Pitout, JDD, Laupland, KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8(3):159166.
9. Gupta, N, Limbago, BM, Patel, JB, Kallen, AJ. Carbapenem-resistant Enterohacteriaceae. epidemiology and prevention. Clin Infect Dis 2011;53(1):6067.
10. Lledo, W, Hernandez, M, Lopez, E. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterohacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 2009;58(10):256260.
11. Mulvey, MR, Simor, AE. Antimicrobial resistance in hospitals: how concerned should we be? CMAJ 2009;180(4):408415.
12. Nadkarni, AS, Schliep, T, Khan, L, Zeana, CB. Cluster of bloodstream infections caused by KPC-2 carbapenemase-producing Klebsiella pneumoniae in Manhattan. Am J Infect Control 2009; 37(2):121126.
13. Bratu, S, Landman, D, Haag, R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005;165: 14301435.
14. Centers for Disease Control and Prevention. Carbapenem-resistant Klebsiella pneumoniae associated with a long-term-care facility: West Virginia, 2009-2011. MMWR Morb Mortal Wkly Rep 2011;306(23):25582560.
15. Chitnis, AS, Caruthers, PS, Rao, AK, et al. Outbreak of carbapenem-resistant Enterohacteriaceae at a long-term acute care hospital: sustained reductions in transmission through active surveillance and targeted interventions. Infect Control Hosp Epidemiol 2012;33(10):984992.
16. Masterton, R. The importance and future of antimicrobial surveillance studies. Clin Infect Dis 2008;47(suppl 1):S21S31.
17. Arnold, R, Thorn, K, Sharma, S, Morgan, DJ. Emergence of Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria. Southern Med 2011;104(1):4045.
18. Hidron, AI, Edwards, JR, Patel, J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29(11):9961011.
19. Sahm, DF, Marsilio, MK, Piazza, G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database—USA. Clin Infect Dis 1999; 29(2):259263.
20. Klein, E, Smith, DL, Laxminarayan, R. Community-associated methicillin-resistant Staphylococcus aureus in outpatients, United States, 1999-2006. Emerg Infect Dis 2009;15(12):19251930.
21. Hoffmann, MS, Eber, MR, Laxminarayan, R. Increasing resistance of Acinetobacter species to imipenem in United States hospitals, 1999-2006. Infect Control Hosp Epidemiol 2010;31(2):196197.
22. Jones, ME, Draghi, DC, Karlowsky, JA, Sahm, DF, Bradley, JS. Prevalence of antimicrobial resistance in bacteria isolated from central nervous system specimens as reported by U.S. hospital laboratories from 2000 to 2002. Ann Clin Microbiol Antimicrob 2004;3:3.
23. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: 20th Informational Supplement. Wayne, PA: CLSI, 2010.
24. Sauerbrei, W, Royston, P, Binder, H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med 2007;26:55125528.
25. Snitkin, ES, Zelazny, AM, Thomas, PJ, et al. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transi Med 2012;4(148):148116.
26. Winokur, PL, Canton, R, Casellas, JM, Legakis, N. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001;32(suppl 2):S94S103.
27. Marquez, P, Terashita, D, Dassey, D, Mascola, L. Community-wide Laboratory Surveillance of Carbapenem-Resistant Klebsiella pneumoniae (CRKP): Los Angeles County 2010. In: Program and abstracts of the 21st Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA); April 1-4, 2011; Dallas, TX; Abstract 359.
28. Sun, L, Klein, EY, Laxminarayan, R. Seasonality and temporal correlation between community antibiotic use and resistance in the United States. Clin Infect Dis 2012;55(3):18.
29. Boyd, LB, Atmar, RL, Randall, GL, et al. Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location. BMC Infect Dis 2008;8:4.
30. Castanheira, M, Mendes, RE, Woosley, LN, Jones, RN. Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007-09). J Antimicrob Chemother 2011;66(6):14091411.
31. Jones, RN, Sader, HS, Fritsche, TR. Occurrences of Extended Spectrum and Other Beta-Lactamases among Enterobacteriaceae Isolated in USA Medical Centers: 10-Year Report from the SENTRY Antimicrobial Surveillance Program. In: Program and abstracts of the 45th Annual Meeting of the Infectious Disease Society of America; 2007; San Diego, CA; Abstract 473.
32. Rhomberg, PR, Jones, RN. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 2009;65(4):414–26.
33. Bulik, CC, Fauntieroy, KA, Jenkins, SG, et al. Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods. J Clin Microbiol 2010;48(7):24022406.
34. Rhomberg, PR, Moet, GJ, Sader, HS, Farrelll, DJ, Jones, RN. Impact Assessment of Revised CLSI Cephalosporin Breakpoints (M100-S20, 2010) Using 27,415 Enterobacteriaceae Isolates Tested in the SENTRY Antimicrobial Surveillance Program. In: Program and Abstracts of the 48th Annual Meeting of the Infectious Disease Society of America; October 20-24, 2010; Vancouver, BC, Canada; Abstract 1016.
35. Kallen, AJ, Beekmann, SE, Limbago, B, et al. Prevalence of beta-lactam nonsusceptible gram-negative bacilli and use and interpretation of current susceptibility breakpoints: a survey of infectious disease physicians. Diagn Microbiol Infect Dis 2011; 71(3):316319.
36. Master, RN, Draghi, DC, Jones, ME, et al. Tracking the implementation of NCCLS M100-S12 expanded-spectrum cephalosporin MIC breakpoints for nonmeningeal isolates of Streptococcus pneumoniae by clinical laboratories in the United States during 2002 and 2003. Ann Clin Microbiol Antimicrobial 2004;3:1.
37. Bell, JM, Chitsaz, M, Turnidge, JD, et al. Prevalence and significance of a negative extended-spectrum beta-lactamase (ESBL) confirmation test result after a positive ESBL screening test result for isolates of Escherichia coli and Klebsiella pneumoniae: results from the SENTRY Asia-Pacific Surveil. J Clin Microbiol 2007; 45(5):14781482.
38. Munier, GK, Johnson, CL, Snyder, JW, et al. Positive extended-spectrum-beta-lactamase (ESBL) screening results may be due to AmpC beta-lactamases more often than to ESBLs. J Clin Microbiol 2010;48(2):673674.
39. Centers for Disease Control and Prevention. Carbapenem-resistant enterobacteriaceae containing New Delhi metallo-beta-lactamase in two patients-Rhode Island, March 2012. MMWR Morb Moral Wkly Rep 2012;61(24):446448.
40. Schwaber, MJ, Lev, B, Israeli, A, et al. Containment of a countrywide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 2011;52(7):848855.

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed